

CITATION REPORT

List of articles citing

**Sildenafil citrate and blood-pressure-lowering drugs:
results of drug interaction studies with an organic
nitrate and a calcium antagonist**

DOI: 10.1016/s0002-9149(99)00044-2

American Journal of Cardiology, 1999, 83, 21C-28C.

Source: <https://exaly.com/paper-pdf/30566181/citation-report.pdf>

Version: 2024-04-24

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
244	Tissue distribution of phosphodiesterase families and the effects of sildenafil on tissue cyclic nucleotides, platelet function, and the contractile responses of trabeculae carneae and aortic rings in vitro. <i>American Journal of Cardiology</i> , 1999 , 83, 3C-12C	3	384
243	Efficacy and safety of sildenafil citrate in the treatment of erectile dysfunction in patients with ischemic heart disease. <i>American Journal of Cardiology</i> , 1999 , 83, 29C-34C	3	157
242	Overall cardiovascular profile of sildenafil citrate. <i>American Journal of Cardiology</i> , 1999 , 83, 35C-44C	3	244
241	Medical treatment of erectile dysfunction. 1999 , 31, 388-98		24
240	Viagra and Cardiovascular Disease. 1999 , 4, 259-267		12
239	Hypotensive interaction of sildenafil and nicorandil in rats through the cGMP pathway but not by K(ATP) channel activation. 2000 , 84, 316-24		12
238	Safety of sildenafil. 2000 , 10, 613-5		2
237	Effect of sildenafil citrate on blood pressure and heart rate in men with erectile dysfunction taking concomitant antihypertensive medication. Sildenafil Study Group. 2000 , 18, 1865-9		77
236	Cardiovascular risk and sildenafil. <i>American Journal of Cardiology</i> , 2000 , 86, 57F-61F	3	65
235	Effect of sildenafil on coronary active and reactive hyperemia. 2000 , 279, H2319-25		21
234	Interaction of L-Arginine and Phosphodiesterase Inhibitors in Vasodilation of the Porcine Internal Mammary Artery. 2000 , 90, 840-846		9
233	The treatment of hypertension in patients with erectile dysfunction. 2000 , 16 Suppl 1, s31-6		19
232	Sex and the patient with cardiovascular risk factors: focus on sildenafil. 2000 , 109 Suppl 9A, 13S-21S; discussion 29S-30S		32
231	Erectile dysfunction: a review of a common problem in rapid evolution. 2000 , 7, 124-129		4
230	Relaxation induced by cGMP phosphodiesterase inhibitors sildenafil and zaprinast in human vessels. 2000 , 70, 1327-31		33
229	Timing of sildenafil therapy in dialysis patients-lessons following an episode of hypotension. 2000 , 15, 926-7		17
228	Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. 2000 , 38, 41-57		623

227	Sildenafil citrate potentiates the hypotensive effects of nitric oxide donor drugs in male patients with stable angina. 2000 , 36, 25-31	146
226	A risk-benefit assessment of sildenafil in the treatment of erectile dysfunction. 2001 , 24, 255-65	3
225	Efectividad del tratamiento con sildenafil en pacientes con disfunci3n er3ctil e hipertensi3n arterial. 2001 , 18, 65-71	
224	Effect of sildenafil citrate (Viagra) on the ocular circulation. 2001 , 131, 751-5	126
223	Sildenafil citrate: a therapeutic update. 2001 , 23, 2-23	65
222	Interactions of sildenafil and tacrolimus in men with erectile dysfunction after kidney transplantation. 2001 , 58, 589-93	14
221	Augmentation of nitric oxide to treat detrusor-external sphincter dyssynergia in spinal cord injury. 2001 , 357, 1964-7	26
220	Oral drug therapy for erectile dysfunction. 2001 , 28, 321-34	71
219	Disfunci3n sexual en la hipertensi3n y beneficios del tratamiento con sildenafil. 2001 , 18, 59-62	
218	Potential of sildenafil-induced hypotension is minimal with nitrates generating a radical intermediate. 2001 , 38, 149-55	13
217	Adrenoceptor antagonists and antianginal drugs. 2001 , 24, 220-228	
216	Drugs acting on the cerebral and peripheral circulations. 2001 , 229-232	
215	The Dutch cohort of sildenafil users: baseline characteristics. 2001 , 87, 648-53	5
214	The cardiovascular response to sexual activity: do we know enough?. 2001 , 24, 271-5	13
213	Synergistic effects of sildenafil on relaxation of rabbit and rat cavernosal smooth muscles when combined with various vasoactive agents. 2001 , 88, 596-601	1
212	Activation of central melanocortin receptors by MT-II increases cavernosal pressure in rabbits by the neuronal release of NO. 2001 , 134, 1705-10	20
211	Effect of sildenafil on blood pressure and arterial wave reflection in treated hypertensive men. 2001 , 15, 707-13	77
210	Male sexual function and its disorders: physiology, pathophysiology, clinical investigation, and treatment. 2001 , 22, 342-88	164

209	Sildenafil (Viagra) augments sodium nitroprusside-induced but not nitroglycerin-induced hypotension in dogs. 2002 , 94, 1505-9, table of contents	1	
208	Sildenafil (Viagra) Augments Sodium Nitroprusside-Induced But Not Nitroglycerin-Induced Hypotension in Dogs. 2002 , 94, 1505-1509	9	
207	Effect of sildenafil citrate (Viagra) on retinal blood vessel diameter. 2002 , 133, 809-12	54	
206	Effects of sildenafil citrate (viagra) on blood pressure in normotensive and hypertensive men. 2002 , 59, 747-52	58	
205	Phosphodiesterase type 5 as a pharmacologic target in erectile dysfunction. 2002 , 60, 4-11	117	
204	A 4-year update on the safety of sildenafil citrate (Viagra). 2002 , 60, 67-90	188	
203	Safety and Tolerability of Apomorphine SL in Men with Cardiovascular Disorders. 2002 , 1, 28-32	10	
202	Coronary and systemic hemodynamic effects of sildenafil citrate: from basic science to clinical studies in patients with cardiovascular disease. 2002 , 86, 131-41	64	
201	Interactions of sildenafil with various coronary vasodilators in isolated porcine coronary artery. 2002 , 437, 155-63	17	
200	Clinical update on sildenafil citrate. 2002 , 53, 219-23	10	
199	Last performance with VIAGRA: post-mortem identification of sildenafil and its metabolites in biological specimens including hair sample. 2002 , 126, 71-6	36	
198	Interactions between drugs for erectile dysfunction and drugs for cardiovascular disease. 2002 , 14, 178-88	25	
197	Incidence and determinants of sildenafil (dis)continuation: the Dutch cohort of sildenafil users. 2002 , 14, 259-65	69	
196	Endothelium-dependency of yohimbine-induced corpus cavernosum relaxation. 2002 , 14, 295-307	37	
195	The clinical safety of viagra. 2002 , 962, 378-88	33	
194	Erectile dysfunction in the cardiac patient. 2003 , 4, 466-71	16	
193	Sexual activity and cardiovascular disease. <i>American Journal of Cardiology</i> , 2003 , 92, 3M-8M	3	13
192	Sildenafil in patients with cardiovascular disease. <i>American Journal of Cardiology</i> , 2003 , 92, 26M-36M	3	32

191	Cardiovascular effects of tadalafil in patients on common antihypertensive therapies. <i>American Journal of Cardiology</i> , 2003 , 92, 47M-57M	3	85
190	Time course of the interaction between tadalafil and nitrates. 2003 , 42, 1855-60		138
189	Cardiovascular safety of sildenafil. 2003 , 26, 453-60		14
188	Hemodynamic effects of sildenafil in patients with stable ischemic heart disease. 2003 , 90, 153-7		13
187	Effects of sildenafil (viagra) on human myocardial contractility, in vitro arrhythmias, and tension of internal mammaria arteries and saphenous veins. 2003 , 41, 734-43		42
186	Erectile dysfunctions. 2003 , 2, 350-6		2
185	Erectile dysfunction: management update. 2004 , 170, 1429-37		70
184	Sildenafil and cardiovascular events [Drug interactions]. 2004 , 143-149		
183	Therapy of ED: PDE-5 Inhibitors. 2004 , 23, 135-41		24
182	Novel phosphodiesterase type 5 inhibitors: assessing hemodynamic effects and safety parameters. 2004 , 27, 120-5		22
181	Erectile dysfunction in the cardiac patient. 2004 , 30, 50-4		6
180	Erectile dysfunction and cardiovascular disease. 2004 , 79, 782-94		14
179	Reply. 2004 , 43, 2150-2151		2
178	New treatment options for erectile dysfunction in patients with diabetes mellitus. 2004 , 64, 2667-88		69
177	The discovery and development of Viagra® (sildenafil citrate). 2004 , 1-13		4
176	Recreational use of sildenafil by HIV-positive and -negative homosexual/bisexual males. 2004 , 38, 1024-30		49
175	Erectile Dysfunction and Cardiovascular Disease. 2004 , 79, 782-794		49
174	Autonomic control of the cardiovascular system during acclimatization to high altitude: effects of sildenafil. 2004 , 97, 935-40		57

173	Inhibition of angiotensin-converting enzyme and phosphodiesterase type 5 improves endothelial function in heart failure. 2005 , 108, 331-8		39
172	Effect of sildenafil on the isolated rat aortic rings. 2005 , 19, 449-56		10
171	Phosphodiesterase type 5 inhibitors for erectile dysfunction. 2005 , 96, 257-80		153
170	Past, present, and future: a 7-year update of Viagra (sildenafil citrate). 2005 , 59, 680-91		61
169	An oral yohimbine/L-arginine combination (NMI 861) for the treatment of male erectile dysfunction: a pharmacokinetic, pharmacodynamic and interaction study with intravenous nitroglycerine in healthy male subjects. 2005 , 59, 85-93		23
168	A case of erectile dysfunction and risk factors for coronary artery disease. 2005 , 17 Suppl 1, S7-S11		3
167	Sexual dysfunction and cardiac risk (the Second Princeton Consensus Conference). <i>American Journal of Cardiology</i> , 2005 , 96, 313-21	3	216
166	Cardiac safety in clinical trials of phosphodiesterase 5 inhibitors. <i>American Journal of Cardiology</i> , 2005 , 96, 37M-41M	3	36
165	Pharmacology and drug interaction effects of the phosphodiesterase 5 inhibitors: focus on alpha-blocker interactions. <i>American Journal of Cardiology</i> , 2005 , 96, 42M-46M	3	63
164	Sexual dysfunction and cardiac risk (the Second Princeton Consensus Conference). <i>American Journal of Cardiology</i> , 2005 , 96, 85M-93M	3	99
163	Safety and efficacy of vardenafil, a selective phosphodiesterase 5 inhibitor, in patients with erectile dysfunction and arterial hypertension treated with multiple antihypertensives. <i>Journal of Sexual Medicine</i> , 2005 , 2, 856-64	1.1	67
162	[Benefits and risks of nitrate preparations in the treatment of angina pectoris]. 2005 , 46, 713-4		
161	Efficacy, safety and tolerability of sildenafil in Brazilian hypertensive patients on multiple antihypertensive drugs. 2005 , 31, 342-53; discussion 354-5		10
160	Disfunci3 sexual en la hipertensi3 arterial. 2005 , 22, 59-72		4
159	The clinical pharmacokinetics of phosphodiesterase-5 inhibitors for erectile dysfunction. 2005 , 45, 987-1003		127
158	Disfunci3 sexual en la hipertensi3 arterial. 2005 , 22, 59-72		0
157	Effects of combined treatment with sildenafil and itraconazole on the cardiovascular system in telemetered conscious dogs. 2005 , 28, 177-86		3
156	A review of isosorbide dinitrate and hydralazine in the management of heart failure in black patients, with a focus on a new fixed-dose combination. 2006 , 28, 666-78		24

155	Phosphodiesterase type 5 inhibitor sildenafil citrate does not potentiate the vasodilative properties of nebivolol in rat aorta. 2006 , 78, 1103-7	6
154	Cardiovascular safety of sildenafil citrate (Viagra): an updated perspective. 2006 , 68, 47-60	55
153	Sildenafil: from angina to erectile dysfunction to pulmonary hypertension and beyond. 2006 , 5, 689-702	366
152	Sildenafil citrate (Viagra) treatment for erectile dysfunction: An updated profile of response and effectiveness. 2006 , 18, 423-31	26
151	Vasodilatory and hypoglycaemic effects of two pyrano-isoflavone extractives from <i>Eriosema kraussianum</i> N. E. Br. [Fabaceae] rootstock in experimental rat models. 2006 , 67, 610-7	26
150	The problem of polypharmacy in heart failure. 2006 , 8, 217-25	22
149	Phosphodiesterase-5 inhibitors and their hemodynamic effects. 2006 , 8, 345-51	23
148	Relaxation and cyclic GMP levels in response to sildenafil in human pulmonary arteries from donors. 2006 , 530, 259-62	3
147	Negligible pharmacokinetic interaction between oral DA-8159, a new erectogenic, and amlodipine in rats. 2006 , 27, 125-31	2
146	Hypertension, antihypertensive therapy, and erectile dysfunction. 2006 , 57, 47-52	34
145	Erectile dysfunction and hypertension. 2007 , 19, 296-302	67
144	Sildenafil citrate (Viagra) enhances vasodilatation by atrial natriuretic peptide in normal dogs. 2007 , 71, 1965-9	4
143	The role of pharmacokinetics and pharmacodynamics in phosphodiesterase-5 inhibitor therapy. 2007 , 19, 253-64	107
142	Do vardenafil and tadalafil have advantages over sildenafil in the treatment of erectile dysfunction?. 2007 , 19, 281-95	33
141	Helping the failing heart and penis. 2007 , 61, 716-8	
140	Effect of sildenafil citrate (Viagra) on coronary flow in normal subjects. 2008 , 25, 72-6	3
139	Functional and morphological improvement in erectile tissue of hypertensive rats by long-term combined therapy with phosphodiesterase type 5 inhibitor and losartan. <i>Journal of Sexual Medicine</i> , 2007 , 4, 1291-303	1.1 33
138	Phosphodiesterase 5 inhibition in essential hypertension. 2008 , 10, 52-7	27

137	Yohimbine enhances the effect of sildenafil on erectile process in rats. 2008 , 20, 409-17		11
136	PDE5 inhibitors and pulmonary hypertension. 2008 , 5, 171-178		
135	Safety, tolerability and pharmacokinetics of udenafil, a novel PDE-5 inhibitor, in healthy young Korean subjects. 2008 , 65, 848-54		60
134	Prevalence and predictors of potential drug-drug interactions in Regione Emilia-Romagna, Italy. 2008 , 33, 141-51		67
133	Adverse drug reactions in patients with cardiovascular disease. 2008 , 33, 703-68		24
132	An open-label, multicenter, flexible dose study to evaluate the efficacy and safety of Viagra (sildenafil citrate) in Korean men with erectile dysfunction and arterial hypertension who are taking antihypertensive agents. <i>Journal of Sexual Medicine</i> , 2008 , 5, 2405-13	1.1	5
131	Post-marketing surveillance of ischaemic optic neuropathy in male veterans co-prescribed phosphodiesterase-5 inhibitors with organic nitrates or alpha-blockers. 2008 , 31, 241-7		10
130	Sildenafil: a review of its use in pulmonary arterial hypertension. 2008 , 68, 383-97		50
129	Does sildenafil cause myocardial infarction or sudden cardiac death?. 2008 , 8, 1-7		18
128	The use of phosphodiesterase 5 inhibitors with concomitant medications. 2008 , 31, 799-808		49
127	Tadalafil in the treatment of lower urinary tract symptoms and erectile dysfunction. 2008 , 5, 355-365		2
126	[Pharmacological, pharmacokinetic, and clinical profile of tadalafil (Cialis)]. 2008 , 131, 469-77		1
125	Sexual dysfunction: the 'prima ballerina' of hypertension-related quality-of-life complications. 2008 , 26, 2074-84		91
124	Time-dependent interactions of the hypotensive effects of sildenafil citrate and sublingual glyceryl trinitrate. 2009 , 67, 403-12		9
123	Managing Erectile Dysfunction in Patients With Cardiovascular Diseases: The Efficacy and Safety of Phosphodiesterase-5 Inhibitors. 2009 , 3, 201-211		1
122	Efficacy and safety of mirodenafil in men taking antihypertensive medications. <i>Journal of Sexual Medicine</i> , 2010 , 7, 3143-52	1.1	16
121	Update on the clinical utility of sildenafil in the treatment of pulmonary arterial hypertension. 2010 , 4, 61-70		28
120	Pharmacokinetic interaction between 5-[2-propyloxy-5-(1-methyl-2-pyrrolidinyloethylamidosulfonyl)phenyl]-1-methyl-3-propyl-1,6-dihydro-7H-pyrazolo(4,3-d) pyrimidine-7-one (DA-8159) and nitroglycerin in rats. 2005 , 57, 1397-405		

119	The effect of sildenafil citrate administration on selected physiological parameters of exercising Thoroughbred horses. 2010 , 42, 606-12		6
118	Spider-venom peptides as therapeutics. 2010 , 2, 2851-71		212
117	The disposition of three phosphodiesterase type 5 inhibitors, vardenafil, sildenafil, and udenafil, is differently influenced by the CYP3A5 genotype. 2011 , 21, 820-8		12
116	Evaluation of sexual function in hypertensive men receiving treatment: a review of current guidelines recommendation. <i>Journal of Sexual Medicine</i> , 2011 , 8, 2405-14	1.1	19
115	A drug-drug interaction knowledge assessment instrument for health professional students: a Rasch analysis of validity evidence. 2011 , 7, 16-26		12
114	Cardiac arrest associated with sildenafil ingestion in a patient with an abnormal origin of the left coronary artery: case report. 2011 , 11, 49		3
113	The identification of a nitrosated prodrug of the PDE-5 inhibitor aildenafil in a dietary supplement: a Viagra with a pop. 2011 , 54, 735-41		39
112	Pulmonary hypertension, nitric oxide and nitric oxide-releasing compounds. 2011 , 5, 163-71		15
111	Sexual activity and cardiovascular disease: a scientific statement from the American Heart Association. 2012 , 125, 1058-72		202
110	Drug Interactions. 2012 , 239-257		1
109	Preparation, characterization and optimization of sildenafil citrate loaded PLGA nanoparticles by statistical factorial design. 2013 , 21, 68		40
108	SOP conservative (medical and mechanical) treatment of erectile dysfunction. <i>Journal of Sexual Medicine</i> , 2013 , 10, 130-71	1.1	117
107	Identification of a new tadalafil analogue found in a dietary supplement. 2013 , 30, 621-6		19
106	The effect of udenafil on the hemodynamics of healthy male volunteers administered tamsulosin. 2013 , 29, 685-93		3
105	Using a low-sodium, high-potassium salt substitute to reduce blood pressure among Tibetans with high blood pressure: a patient-blinded randomized controlled trial. 2014 , 9, e110131		37
104	Management of erectile dysfunction in hypertension: Tips and tricks. 2014 , 6, 908-15		36
103	Quantification of active pharmaceutical ingredient and impurities in sildenafil citrate obtained from the Internet. 2014 , 5, 180-9		7
102	Isolation and identification of novel propoxyphenyl thiosildenafil found in natural health food product. 2014 , 31, 1-6		18

101	2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2014 , 130, e344-426	754
100	2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2014 , 130, 2354-94	696
99	Total testosterone levels and the effect of sildenafil on type 2 diabetics with erectile dysfunction. 2014 , 29, 46-50	3
98	Biomarkers and human hepatocytes. 2014 , 8, 173-83	8
97	Potential therapeutic role of phosphodiesterase type 5 inhibition in hypertension and chronic kidney disease. 2014 , 63, 5-11	28
96	2014 AHA/ACC Guideline for the Management of Patients With NonST-Elevation Acute Coronary Syndromes: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2014 , 64, 2645-2687	132
95	2014 AHA/ACC Guideline for the Management of Patients with Non-ST-Elevation Acute Coronary Syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2014 , 64, e139-e228	1822
94	Sexual activity and ischemic heart disease. 2014 , 16, 445	15
93	Sildenafil citrate as oral solid lipid nanoparticles: a novel formula with higher bioavailability and sustained action for treatment of erectile dysfunction. 2014 , 11, 1015-22	37
92	Survivorship: sexual dysfunction (male), version 1.2013. 2014 , 12, 356-63	5
91	Impact of nitroglycerin infusion on weaning off hypertensive mechanically ventilated chronic obstructive pulmonary disease patients. 2014 , 63, 969-978	
90	Safety and tolerability considerations in the use of sildenafil for children with pulmonary arterial hypertension. 2015 , 7, 175-83	5
89	Evaluation of Adverse Drug Properties with Cryopreserved Human Hepatocytes and the Integrated Discrete Multiple Organ Co-culture (IdMOC(TM)) System. 2015 , 31, 137-49	16
88	Acute Dietary Nitrate Intake Improves Muscle Contractile Function in Patients With Heart Failure: A Double-Blind, Placebo-Controlled, Randomized Trial. 2015 , 8, 914-20	84
87	Phosphodiesterase type 5 inhibitors and kidney disease. 2015 , 47, 1521-8	25
86	Amlodipine as an antiischemic drug is superior to long acting nitrates. 2015 , 10, 50-56	
85	Sildenafil in the treatment of pressure ulcer: a randomised clinical trial. 2015 , 12, 111-7	16
84	Effect of acute dietary nitrate intake on maximal knee extensor speed and power in healthy men and women. 2015 , 48, 16-21	85

83	Nitrates, organic. 2016 , 192-202	
82	Pharmacology of drugs used for the treatment of erectile dysfunction. 2016 , 48-55	0
81	Sildenafil citrate-Glycyrrhizin/Eudragit binary spray dried microparticles: A sexual behavior studies on male rats. 2016 , 36, 141-149	8
80	Electrochemical determination of sildenafil citrate as standard, in tablets and spiked with human serum at gold and cystein modified gold electrode. 2016 , 782, 103-107	6
79	A Phase I proof-of-concept and safety trial of sildenafil to treat cerebral vasospasm following subarachnoid hemorrhage. 2016 , 124, 318-27	12
78	Visible-Light Photoredox-Catalyzed Aminosulfonylation of Diaryliodonium Salts with Sulfur Dioxide and Hydrazines. 2017 , 359, 1308-1319	97
77	Novel contrast-injection protocol for high-resolution abdominal CT-angiography: vascular visualization improvement with vasodilator. 2017 , 42, 2571-2578	1
76	Current and future therapies for addressing the effects of inflammation on HDL cholesterol metabolism. 2017 , 174, 3986-4006	9
75	Survivorship, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. 2017 , 15, 1140-1163	63
74	Proof of Principle for a Novel Class of Antihypertensives That Target the Oxidative Activation of PKG β Protein Kinase G β 2017 , 70, 577-586	12
73	Chemsex intoxication involving sildenafil as an adulterant of GHB. 2017 , 9, 956-959	15
72	Have you had Viagra within the past 24 hours? 2017 , 9, 490-494	
71	Dietary nitrate-induced increases in human muscle power: high versus low responders. 2018 , 6, e13575	30
70	Radicals and Sulfur Dioxide: A Versatile Combination for the Construction of Sulfonyl-Containing Molecules. 2018 , 24, 11852-11863	152
69	In Vitro Assessment of Pharmacokinetic Drug-Drug Interactions of Direct Oral Anticoagulants: Type 5-Phosphodiesterase Inhibitors Are Inhibitors of Rivaroxaban and Apixaban Efflux by P-Glycoprotein. 2018 , 365, 519-525	16
68	Non-ST-Segment Acute Coronary Syndromes. 2018 , 36, 37-52	16
67	Irradiation-Induced Cardiac Connexin-43 and miR-21 Responses Are Hampered by Treatment with Atorvastatin and Aspirin. 2018 , 19,	16
66	Pharmacodynamic interaction between intravenous nitroglycerin and oral sacubitril/valsartan (LCZ696) in healthy subjects. 2018 , 74, 1121-1130	1

65	Preoperative subcutaneous sildenafil injection increases random flap survival in rats. 2018 , 33, 216-222	8
64	Targeting Myosin by Blebbistatin Derivatives: Optimization and Pharmacological Potential. 2018 , 43, 700-713	40
63	Comparison of enhanced male mice sexual function among three medicinal materials. 2018 , 50, e13087	4
62	A New Perspective on the Nitrate-Phosphodiesterase Type 5 Inhibitor Interaction. 2018 , 23, 375-386	9
61	Synthesis of isotope β -labeled selective PDE5 inhibitor sildenafil (UK 92480-10). 2018 , 106, 851-855	
60	Recent Developments in the Chemistry of Pyrazoles. 2018 , 126, 55-107	15
59	Advances in small-molecule therapy for managing angina pectoris in the elderly. 2019 , 20, 1471-1481	
58	Tadalafil for the treatment of benign prostatic hyperplasia. 2019 , 20, 929-937	12
57	Drug repositioning in pulmonary arterial hypertension: challenges and opportunities. 2019 , 9, 2045894019832226	
56	Cysteine-Based Redox Sensing and Its Role in Signaling by Cyclic Nucleotide-Dependent Kinases in the Cardiovascular System. 2019 , 81, 63-87	12
55	The Serendipitous Story of Sildenafil: An Unexpected Oral Therapy for Erectile Dysfunction. 2019 , 7, 115-128	53
54	A Single Dose of Dietary Nitrate Increases Maximal Knee Extensor Angular Velocity and Power in Healthy Older Men and Women. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2020 , 75, 1154-1160	6.4 16
53	Established and emerging therapeutic uses of PDE type 5 inhibitors in cardiovascular disease. 2020 , 177, 5467-5488	34
52	Simultaneous Pharmacokinetic Analysis of Nitrate and its Reduced Metabolite, Nitrite, Following Ingestion of Inorganic Nitrate in a Mixed Patient Population. 2020 , 37, 235	1
51	Evaluation of knowledge, attitude and practice of healthcare providers towards life-threatening drug-drug interactions in Penang General Hospital, Malaysia. 2020 , 8, 1253-1258	2
50	PDE5 inhibition improves cardiac morphology and function in SHR by reducing NHE1 activity: Repurposing Sildenafil for the treatment of hypertensive cardiac hypertrophy. 2021 , 891, 173724	2
49	The effect of selected drugs on the mitigation of myocardial injury caused by gamma radiation. 2021 , 99, 80-88	0
48	Visible-light-promoted three-component cycloaddition reaction: synthesis of 4-functionalized 1,5-disubstituted 1,2,3-triazoles.	0

47	Sildenafil citrate in healthy and diseased hearts. 2021 , 6, 033-039		0
46	Erectile Dysfunction A Prospective Randomized Placebo-Controlled Study Evaluating the Effect of Low-Intensity Extracorporeal Shockwave Therapy (LI-ESWT) in Men With Erectile Dysfunction Following Radical Prostatectomy. 2021 , 9, 100338		3
45	Eco-friendly stability-indicating RP-HPTLC method for sildenafil analysis, characterization and biological evaluation of its oxidized stress degradation product. 2021 , 11, 15358		0
44	Cardiovascular Outcome Risks in Patients With Erectile Dysfunction Co-Prescribed a Phosphodiesterase Type 5 Inhibitor (PDE5i) and a Nitrate: A Retrospective Observational Study Using Electronic Health Record Data in the United States. <i>Journal of Sexual Medicine</i> , 2021 , 18, 1511-1523	1.1	2
43	Potential Cardiac Applications of Phosphodiesterase Type-5 Inhibition. 2004 , 207-237		1
42	Cardiovascular Safety of Phosphodiesterase-5 Inhibitors. 2004 , 139-161		1
41	Atrial fibrillation and continuous hypotension induced by sildenafil in an intermittent WPW syndrome patient. <i>International Heart Journal</i> , 1999 , 40, 827-30		16
40	Compatibility Studies of Sildenafil with Different Excipients by Using TGA, DSC, XRD and FTIR. <i>Celal Bayar Universitesi Fen Bilimleri Dergisi</i> , 2019 , 15, 401-407	0.1	3
39	Sexual function in hypertensive patients receiving treatment. <i>Vascular Health and Risk Management</i> , 2006 , 2, 447-55	4.4	31
38	Russian clinical guidelines Coronary artery bypass grafting in patients with ischemic heart disease: rehabilitation and secondary prevention. <i>Cardiosomatics</i> , 2016 , 7, 5-71	0.4	35
37	Changes of microRNA-1, -15b and -21 levels in irradiated rat hearts after treatment with potentially radioprotective drugs. <i>Physiological Research</i> , 2016 , 65 Suppl 1, S129-37	2.1	17
36	Lessons of the month 3: Intravenous poppers abuse: case report, management and possible complications. <i>Clinical Medicine</i> , 2020 , 20, 221-223	1.9	2
35	Herzkrankheiten und Sexualität Gefäßrdung des kranken Herzens durch Sexualität oder Gefäßrdung der Sexualität durch das kranke Herz. 2001 , 177-184		
34	Therapie. 2002 , 129-246		
33	Safety and Hemodynamic Effects of Sildenafil in Patients With Coronary Artery Disease. 2004 , 179-194		
32	Cardiovascular Safety of Sexual Activity and Phosphodiesterase Type 5 Inhibition. 2004 , 159-181		
31	Sexual Activity As a Trigger of Myocardial Infarction/Ischemia. 2004 , 251-260		
30	Cardiovascular safety of sildenafil in the treatment of erectile dysfunction. 2004 , 151-162		

- 29 The Hemodynamics of Phosphodiesterase-PDE5 Inhibitors. **2004**, 131-137
- 28 Sildenafil Citrate and the Nitric Oxide/Cyclic Guanosine Monophosphate Signaling Pathway. **2004**, 89-116
- 27 Oral Type 5 Phosphodiesterase Therapy for Male and Female Sexual Dysfunction. **2004**, 107-119
- 26 Sildenafil. **2006**, 3133-3137
- 25 Nitrates, organic. **2006**, 2529-2537
- 24 DRUGS THAT ACT ON THE CEREBRAL AND PERIPHERAL ARTERIAL AND VENOUS CIRCULATIONS. **2009**, 431-448
- 23 Drugs Used to Treat Hypertension, Heart Failure, and Angina Pectoris. **2009**, 1-196
- 22 NHG-Standaard Erectiele disfunctie. **2009**, 1291-1313
- 21 NHG-Standaard Erectiele disfunctie. **2011**, 1495-1517
- 20 Antihypertensives and Prostanoids. **2011**, 221-250
- 19 Discovering Complex Relationships of Drugs over Distributed Knowledgebases. *International Journal of Distributed Systems and Technologies*, **2014**, 5, 22-39 0.3
- 18 NO and ART. *Springer Briefs in Molecular Science*, **2015**, 13-28 0.6
- 17 Discovering Complex Relationships of Drugs over Distributed Knowledgebases. **2016**, 1572-1591
- 16 Phosphodiesterase type V inhibitors. **2016**, 734-742
- 15 A single dose of dietary nitrate increases maximal muscle speed and power in healthy older men and women.
- 14 [Cardiovascular safety of the recreational use of cannabis associated to sildenafil: Systematic review]. *Revista Internacional De Andrología*, **2020**, 18, 75-78 0.6
- 13 Dose-response effect of dietary nitrate on muscle contractility and blood pressure in older subjects. 0
- 12 Dose-Response Effect of Dietary Nitrate on Muscle Contractility and Blood Pressure in Older Subjects: A Pilot Study. *Journals of Gerontology - Series A Biological Sciences and Medical Sciences*, **2021**, 76, 591-598 6.4 4

11	What happened? Sexual consequences of prostate cancer and its treatment. <i>Canadian Family Physician</i> , 2005 , 51, 977-82	0.9	24
10	Viagra and broken hearts. <i>Canadian Family Physician</i> , 2000 , 46, 257-9, 267-9	0.9	1
9	How does this happen? Part I: mechanisms of adverse drug reactions associated with psychotropic medications. <i>Journal of the Canadian Academy of Child and Adolescent Psychiatry</i> , 2010 , 19, 40-5	0.7	4
8	Sildenafil Effect on Nitric Oxide Secretion by Normal Human Endometrial Epithelial Cells Cultured In vitro. <i>International Journal of Fertility & Sterility</i> , 2011 , 5, 142-7	1.9	10
7	Advances in the photoredox catalysis of S(VI) compounds. <i>Tetrahedron</i> , 2022 , 111, 132711	2.4	1
6	Organic and dietary nitrates, inorganic nitrite, nitric oxide donors, and soluble guanylate cyclase stimulation. 2022 , 807-828		
5	Self-nanoemulsifying formulation for oral delivery of sildenafil: effect on physicochemical attributes and in vivo pharmacokinetics.		0
4	Two Versatile Pencil Graphite Polymer Sensor Electrodes Coupled with Potentiometry and Potentiometric Titration Methods: Profiling Determinations of Vitamin V in Tablets and Urine Samples. 2022 , 22, 9128		0
3	The action of phosphodiesterase-5 inhibitors on Amyloid pathology and cognition in experimental Alzheimer's disease: A systematic review. 2023 , 320, 121570		0
2	The influence of acute dietary nitrate supplementation on skeletal muscle fatigue and recovery in older women.		0
1	Phosphodiesterase Type 5 Inhibitors and Oral Nitrates in Male Patients with Ischemic Heart Disease.		0